Abivax SA (ABVX)
113.35
-0.95
(-0.83%)
USD |
NASDAQ |
Aug 28, 16:00
113.39
+0.04
(+0.04%)
After-Hours: 20:00
Abivax Shareholders Equity (Quarterly) : 494.98M for March 31, 2026
Shareholders Equity (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Shareholders Equity (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2026 | 494.98M |
| December 31, 2025 | 534.62M |
| September 30, 2025 | 600.70M |
| Date | Value |
|---|---|
| June 30, 2025 | -56.67M |
| March 31, 2025 | -7.121M |
Shareholders' Equity Definition
Represents the value of Shareholders' Equity as of the close of the report date, belonging to both Preferred and Common Equity Shareholders.
Shareholders Equity (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Shareholders Equity (Quarterly) Benchmarks
| Poxel SA | -- |
| OSE Immunotherapeutics SA | -- |
| Cogent Biosciences, Inc. | 532.39M |
| Compass Pathways Plc | 84.53M |
| Vera Therapeutics, Inc. | 407.76M |
Shareholders Equity (Quarterly) Related Metrics
| Total Assets (Quarterly) | 630.42M |
| Total Liabilities (Quarterly) | 135.44M |
| Debt to Equity Ratio | 0.0796 |
| Current Ratio | 8.247 |
| Net Debt Paydown Yield | 0.09% |